160 related articles for article (PubMed ID: 38683493)
1. PB006: A Natalizumab Biosimilar.
Shirley M
Clin Drug Investig; 2024 May; 44(5):367-370. PubMed ID: 38683493
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial.
Wessels H; von Richter O; Velinova M; Höfler J; Chamberlain P; Kromminga A; Lehnick D; Roth K
Expert Opin Biol Ther; 2023; 23(12):1287-1297. PubMed ID: 38044885
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.
Hemmer B; Wiendl H; Roth K; Wessels H; Höfler J; Hornuss C; Liedert B; Selmaj K
JAMA Neurol; 2023 Mar; 80(3):298-307. PubMed ID: 36689214
[TBL] [Abstract][Full Text] [Related]
4. AVT02: An Adalimumab Biosimilar.
Kang C
Clin Drug Investig; 2022 Oct; 42(10):875-878. PubMed ID: 36181655
[TBL] [Abstract][Full Text] [Related]
5. 4-Week toxicity study of biosimilar natalizumab in comparison to Tysabri
Grabowski T; Leuschner J; Gad S
Drug Chem Toxicol; 2022 Mar; 45(2):499-506. PubMed ID: 32024395
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study.
Saida T; Kira JI; Kishida S; Yamamura T; Sudo Y; Ogiwara K; Tibung JT; Lucas N; Subramanyam M;
Mult Scler Relat Disord; 2017 Jan; 11():25-31. PubMed ID: 28104251
[TBL] [Abstract][Full Text] [Related]
7. CT-P10 (Truxima™): A Rituximab Biosimilar.
Deeks ED
BioDrugs; 2017 Jun; 31(3):275-278. PubMed ID: 28497220
[TBL] [Abstract][Full Text] [Related]
8. SB5: An Adalimumab Biosimilar.
Frampton JE
BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
[TBL] [Abstract][Full Text] [Related]
9. GP2013: A Rituximab Biosimilar.
Blair HA
BioDrugs; 2017 Oct; 31(5):465-468. PubMed ID: 28921160
[TBL] [Abstract][Full Text] [Related]
10. PF-06410293: An Adalimumab Biosimilar.
Lee A; Shirley M
BioDrugs; 2020 Oct; 34(5):695-698. PubMed ID: 32949384
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.
McCormack PL
Drugs; 2013 Sep; 73(13):1463-81. PubMed ID: 23912625
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab in relapsing-remitting multiple sclerosis.
Outteryck O
Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
[TBL] [Abstract][Full Text] [Related]
13. PF-06438179/GP1111: An Infliximab Biosimilar.
Al-Salama ZT
BioDrugs; 2018 Dec; 32(6):639-642. PubMed ID: 30284704
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
Lanza Cariccio V; Bramanti P; Mazzon E
Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
[TBL] [Abstract][Full Text] [Related]
15. PF-05280014: A Trastuzumab Biosimilar.
Paik J
BioDrugs; 2018 Oct; 32(5):515-518. PubMed ID: 30280367
[TBL] [Abstract][Full Text] [Related]
16. GP2017: An Adalimumab Biosimilar.
Heo YA
BioDrugs; 2018 Dec; 32(6):635-638. PubMed ID: 30460599
[TBL] [Abstract][Full Text] [Related]
17. GP2015: An Etanercept Biosimilar.
Deeks ED
BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.
Ghezzi A; Comi G; Grimaldi LM; Moiola L; Pozzilli C; Fantaccini S; Gallo P
Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):e591. PubMed ID: 31355324
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
[TBL] [Abstract][Full Text] [Related]
20. Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab.
Fiander MDJ; Bhan V; Stewart SA; Parks NE
Can J Neurol Sci; 2019 Jul; 46(4):455-458. PubMed ID: 31113500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
